3323. Package # 370 (PCR. STI + HPV HCR)

Package No. 370 – comprehensive PCR diagnostics for major STIs (chlamydia, gonorrhea, trichomoniasis, mycoplasmosis) and 14 high-risk HPV genotypes. Recommended for complaints or suspected infections, or for pre-pregnancy screening.

Package No. 370 combines two key diagnostic approaches.

1. PCR test for STIs (qualitative detection):

• Chlamydia trachomatis;
• Neisseria gonorrhoeae;
• Trichomonas vaginalis;
• Mycoplasma genitalium.

2. PCR analysis for 14 high-risk HPV genotypes (real-time quantitative genotyping):

• HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.

The combination of qualitative PCR for STI pathogens and quantitative HPV viral load tests allows for:

• detection of active infectious processes;
• assessment of cancer risks;
• prescribing targeted therapy;
• monitoring treatment effectiveness.

What is the test needed for:

• diagnosis of the causes of chronic pelvic inflammation;
• identification of pathogens of sexually transmitted infections;
• screening for high-risk HPV, the main etiologic factor for cervical cancer;
• prevention of infections in sexual partners;
• monitoring of patients with suspected cervical epithelial pathologies.

• Patients with STI symptoms (abnormal discharge, pain, dysuria, itching).
• Partners of individuals with confirmed STIs.
• Women planning pregnancy or in the early stages of pregnancy.
• In cases of infertility or menstrual irregularities.
• Young women under 25 who are single.
• If infectious and inflammatory diseases of the cervix, vagina, or urethra are suspected.
• For routine HPV screening as part of cervical cancer prevention.

• Scrapes from various sites depending on the test

Women